Note: Source:

A study on new products

available in India for diabetics

Note: Source: Source: Novo Nordisk

In one generation, the prevalence of diabetes has increased SIX fold

Note: Source:

In the year 2000, there were 171 Million diabetics in the world. The number is expected to increase to 366 Million by 2030. India, China and United States account for 30% of the world’s diabetic population

Source: World Health Organization; Grail Research Analysis

Africa 2000: 7.0 Million 2030: 18.2 Million

The Americas 2000: 33.0 Million 2030: 66.8 Million

Europe 2000: 33.3 Million 2030: 48.0 Million

Australia 2000: 1.0 Million 2030: 1.7 Million

The Middle East 2000: 15.2 Million 2030: 42.6 Million

Asia 2000: 81.7 Million 2030: 188.8 Million

Incidence of Diabetes

Note: Source:

It is estimated that India will continue to have the largest number of diabetics in the world, even in 2030

Ranking Country People with Diabetes

(MM) Year – 2000

People with Diabetes (MM)

Year – 2030

1 India 31.7 79.4

2 China 20.8 42.3

3 USA 17.7 30.3

Diabetes is most prevalent in the following 10 countries: India China USA Indonesia Japan Pakistan Russia Brazil Italy Bangladesh

Prevalence of Diabetes

Source: World Health Organization

Note: Source:

Rapid urbanization and industrialization

leads to lifestyle changes which adversely

affect the risk factors associated with diabetes. – Dr A. Ramachandran of Chennai’s Diabetes Research Centre and M.V. Hospital For Diabetes

“

In areas such as the Middle East and countries in the Pacific region, one out of four deaths for 35-64 year-olds is due to diabetes

Cardiovascular disease is the cause of 50-80% of all deaths among diabetics

The Major Diabetic Complications

” Eyes (Retinopathy)

Heart & Coronary Circulation

(Coronary Heart disease)

Kidney (Nephropathy)

Lower Limbs (Peripheral

Vascular Disease)

Peripheral Nervous System (Neuropathy)

Feet (Diabetic Foot – Ulceration and Amputation)

Brian and Cerebral Circulation (Cerebrovascular Disease)

Various studies have shown that the high incidence of diabetes in India is mainly

because of sedentary lifestyle, lack of physical

activity, obesity, stress and consumption of diets rich in fat, sugar and calories. – Hindustan Times

“ ” Source: Business World; International Diabetes Federation; Hindustan Times;

World Health Organization

Note: Source:

Global spending on diabetes treatment is expected to increase from USD 232 Bn in 2007 to USD 303 Bn in 2025

Loss in 2005

Loss in 2015

Average Annual Loss

Income Loss as a % of GDP

in 2015

China 18.0 126.0 53.5 1.2

Russia 11.0 66.0 29.8 5.3

India 8.7 54.0 23.0 1.3

Brazil 2.7 9.3 5.1 0.5

U.K. 1.6 6.4 3.4 0.3

Pakistan 1.2 6.7 3.0 1.0

Canada 0.5 1.5 0.9 0.2

Nigeria 0.4 1.5 0.8 0.7

Tanzania 0.1 0.5 0.2 0.9

Projected Loss in National Income Due to Chronic Diseases (USD Bn)

Source: Indian Council For Research On International Economic Relations; Novo Nordisk; International Diabetes Federation

Note: Source:

The Indian market for oral diabetes treatments is growing at an annual rate of 14%, more than double the 6.3% global growth rate

US

D B

n

7.70 8.19

5.866.83

0

24

6

8

1012

14

16

2004 2005

US

D B

n

Insulin Oral drugs1

15.00 13.57

0.43 0.48

Note: 1Oral antibiotic drugs; 2Converted to USD using average rate of conversion for the period October 2006-October 2007; 3Oral Hypoglycemic Agents (OHA) Source: The World Diabetes Market, 2005-2011; PwC; The Financial Express; dLife; Global Forum for Health; Centre for Prevention and Health Services

Global Market for Diabetes Drugs (USD Bn)

Indian Market for Diabetes Drugs (USD Bn)

Insulin Oral drugs3

0.33 0.38

0.0950.104

0

0.1

0.2

0.3

0.4

0.5

0.6

2007 2008E2

In 2005, the mean estimated annual cost for diabetes per individual in India was USD 418 • Indirect costs, which include measures of productivity and income loss through illness, represented USD 267 per

individual • Direct costs such as drug treatment, check-ups, etc. approximated USD 99 per individual • Hospitalization costs were estimated to be USD 51

In the US, diabetics spend an average of USD 13,243 on healthcare every year, well above the estimated annual healthcare expense of USD 2,560 associated with non-diabetics

Note: Source:

Diabetes Products for

In 2003, there were 189 million diabetics in the world. The projected figure for 2025 is 324 million. And we have reason to believe that the projection is an underestimation.

– Prof. Lefebvre, President, International Diabetes Federation

Sugar-free products are selling the fastest in the health food category… In the last two years,

the sale of health food has shot up by about 40 percent. – Rajesh Sanklecha, Manager, Nuts ‘n Spices, a department store chain in India

“

“

”

” Source: The Hindu; Business Line

Note: Source:

Amul is India’s top brand according to a 2007 Brand Survey1 Amul, which means ‘priceless’, is derived from the Sanskrit

word ‘Amoolya’ It is a brand of Gujarat Cooperative Milk Marketing Federation

(GCMMF) GCMMF’s 2.6 MM producer members collected 2.38 Bn liters of

milk in 2006-2007, a daily collection average of 6.5 MM liters In the financial year 2006-2007, GCMMF posted sales of

USD1.05 Bn

Amul ventured into sugar free desserts through Amul Sugar Free Probiotic Frozen Desserts and has now also launched sugar free chocolates aimed specifically at diabetics

Notes: 1Asia’s Top 1000 Brands Survey by ‘Media’, Asian Integrated Media Ltd and Synovate

Source: Amul website; Synovate website

Note: Source:

The Saffola brand belongs to Marico Industries, one of India’s leading FMCG companies, generating 2006-2007 revenue of USD 380 MM

Saffola launched Atta (Wheat flour) additives to help control sugar and cholesterol levels

• The staple use of Atta is to make rotis (a type of Indian bread) which is widely used in daily foods all over India

India consumed approximately 40 million tons of Atta in 2004

Source: Saffola website; Marico industries website; Business Line

Brands like Saffola have launched innovative food additives for sugar management. Variants of this product are also available to help control cholesterol intake.

Source: Saffola website; Marico industries website; Business Line

Print Ad

Note: Source:

Nouveau Diététique’s product portfolio includes offerings geared for diabetics and obese people, ranging from diabetic dietary supplements to sugar-free chocolate

Source: Nouveau Diététique website

Soluble fibers like Galactomannan are believed to help slow down the conversion of carbohydrates to glucose and hence improve its subsequent absorption

It is unnerving to find that some 10 year olds are diagnosed with

diabetes. Nouveau Diététique would like to reverse this scenario by

introducing tasty and healthy substitutes to the unhealthy

foods we are eating today - Nouveau Diététique Website ” “

Note: Source:

Horlicks lite health food drink and Horlicks lite Bite biscuits have been formulated for the nutritional needs of adults and are promoted for safe use by diabetics

Horlicks, one of India’s leading health food drinks, is a brand of GlaxoSmithKline’s Consumer Healthcare division

In 2004, Horlicks controlled more than half of the Indian health food drink market1

Horlicks launched two diabetic-friendly products in September 2005 – Horlicks Lite health food drink and Horlicks Lite Bite biscuits

Both products are endorsed and certified by Diabetes India, the largest body of participating endocrinologists, medical specialists, physicians and researchers interested in the study of diabetes

Note: 1The Economic Times Survey, 2004 Source: GlaxoSmithKline Consumer Healthcare India website

Note: Source:

With India being termed the ‘Diabetes Capital of the World’, insurance companies such as ICICI Prudential have introduced new insurance products specifically tailored to diabetics

ICICI Prudential Life Insurance is a joint venture between Prudential plc, an international financial services group, and ICICI Bank, one of India’s leading financial services companies

ICICI Prudential is ranked second1 among the insurance sector companies of India

In November 2006, ICICI Prudential launched India’s first insurance policy specifically tailored to the needs of diabetics

ICICI Prudential currently offers two types of insurance policies for diabetics:

• Diabetes Care: Critical illness insurance policy for Type 2 diabetics and pre-diabetics

• Diabetes Care Plus: Critical illness and death insurance policy for Type 2 diabetics and pre-diabetics

Notes: 1According to the Businessworld’s Most Respected Company Survey of 2006 Source: ICICI Prudential website; Businessworld; DNA India website

Note: Source:

Type 1 Diabetes Type 1 diabetes is usually diagnosed in children or young

adults and was formerly referred to as juvenile diabetes People suffering from type 1 diabetes either produce very little

or no insulin at all Daily injections of insulin are required to manage the disease Some of the symptoms of type 1 diabetes include excessive

thirst; constant hunger; excessive urination; weight loss for no reason; rapid, hard breathing; vision changes; drowsiness or exhaustion

Type 2 Diabetes People suffering from type 2 diabetes are unable to use the insulin produced in

the body effectively It is possible to manage this type of diabetes with lifestyle changes and oral

drugs, although insulin may also be required Symptoms of type 2 diabetes are similar to type 1 diabetes, though less obvious

• Often, people with type 2 diabetes have no symptoms and the disease goes undiagnosed for a long period after its onset

Gestational Diabetes Gestational diabetes mellitus (GDM) develops during pregnancy and usually

goes away after pregnancy The chances of GDM sufferers developing type 2 diabetes in the future is high GDM affects around 4% of pregnant women in US every year

Types of Diabetes Source: American Diabetes Association; World Health Organization

Done

For More Information Contact:

Grail Research (info@grailresearch.com)

Copyright © 2007 by Grail Research, a division of Integreon

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means — electronic, mechanical, photocopying, recording, or otherwise — without the permission of Grail Research, a division of Integreon